|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/724 | |
| A61P 35/00 | |||
| A61K 47/61 |
| (11) | Number of the document | 2477985 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10817784.1 |
| Date of filing the European patent application | 2010-09-15 | |
| (97) | Date of publication of the European application | 2012-07-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-11-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/048973 |
| Date | 2010-09-15 |
| (87) | Number | WO 2011/034954 |
| Date | 2011-03-24 |
| (30) | Number | Date | Country code |
| 242752 P | 2009-09-15 | US | |
| 317039 P | 2010-03-24 | US | |
| 332150 P | 2010-05-06 | US | |
| 381851 P | 2010-09-10 | US |
| (72) |
YEN, Yun, US
SCHLUEP, Thomas, US
RYAN, John, US
DAVIS, Mark, US
OLIVER, James, C., US
|
| (73) |
BlueLink Pharmaceuticals, Inc.,
2503 S. Loop Drive, Ste 5100, Ames, Iowa 50010,
US
|
| (54) | CRLX101 FOR USE IN THE TREATMENT OF CANCER |
| CRLX101 FOR USE IN THE TREATMENT OF CANCER |